Is this a new threat for CSL shares?

There's a new wonder drug on the scene. Should shareholders be concerned?

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are ending the week in the red.

At the time of writing, the biotechnology giant's shares are down almost 2% to $281.78.

Why are CSL shares falling?

With no news out of the company, it isn't clear why its shares are under pressure today.

But given how some analysts believe that weight loss drugs could have a negative impact on the company's sales, it's possible that news of a new wonder drug could be weighing on sentiment.

Earlier this week, Viking Therapeutics (NASDAQ: VKTX) shares rocketed over 100% after announcing positive top-line results from its phase 2 clinical trial of VK2735.

It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that is in development for the potential treatment of various metabolic disorders such as obesity.

Viking revealed that the phase 2 trial successfully achieved its primary endpoint and all secondary endpoints. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo.

Importantly, the study showed VK2735 to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorised as mild or moderate.

Is this a threat to CSL?

Opinion remains divided on whether GLP-1s are a threat to CSL and its shares. A number of analysts believe they could be due to the possible kidney benefits resulting from their use. However, CSL doesn't believe this will be the case.

As we covered here late last year, the company's CEO, Paul McKenzie, commented:

There's been a lot of talk about GLP-1s […] To give you the punchline, based on the high-level results, we do not see GLP-1s as having a material impact on the business.

This sentiment was echoed by CSL Vifor general manager, Hervé Gisserot. He said:

In our view, as already stated by Paul, the renal disease market won't be disrupted by GLP-1.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »